Analysis of the level of fructosamine in liver diseases / 中国基层医药

ABSTRACT

Objective@#To investigate the level of fructosamine in different liver diseases.@*Methods@#From October 2016 to October 2017, 153 patients with liver diseases hospitalized in Tongling Municipal Hospital were selected as study group, including 58 patients with chronic hepatitis B(CHB), 35 patients with liver cirrhosis(LC), 60 patients with primary hepatocellular carcinoma(HCC). Meanwhile, 40 healthy subjects were selected as control group.The total protein(TP), albumin (ALB), cystatin C(CysC), sialic acid(SA) and fasting blood glucose(FBG) were statistically analyzed.@*Results@#The difference of fructosamine between the HCC group and the LC group, the CHB group and the control group was statistically significant[(299.1±96.9)μmmol/L, (259.3±41.5)μmmol/L, (248.7±29.5)μmmol/L, (234.9±20.2)μmmol/L](F=11.321, P<0.05). There was no statistically significant difference in FBG between the study group and the control group(P>0.05). Correlation analysis showed that there was a positive correlation between fructosamine and FBG in the CHB group(r=0.655, P<0.05). The fructosamine of LC group was positively correlated with TP, CysC and FBG (r=0.406, 0.418, 0.351, all P<0.05). The fructosamine was correlated with TP, ALB, CysC and SA in HCC group(r=-0.513, -0.610, 0.637, r=0.311, all P<0.05). There was no correlation between fructosamine and FBG in the HCC group (P>0.05). Logistic stepwise regression analysis showed that in the HCC group, fructosamine(OR=1.029, 95% CI 1.007~1.052), CysC (OR=5 454.909, 95% CI 78.117~380 916.873) and SA(OR=1.155, 95% CI 1.047~1.275) were independent risk factors of HCC.@*Conclusion@#It has positive correlation between fructosamine and FBG in CHB and LC patients, fructosamine may not be related to glycometabolism in HCC patients, but the data of fructosamine reflect the degree of glycosylation of HCC tumor cells.